Supplementary Information

Type of Article: Original Research

Title: Efficacy and Safety of Pharmacotherapy in Cancer-Related Anorexia and Cachexia Symptoms: An Updated Systematic Review and Network Meta-Analysis

Running Title: Meta-analysis in Treatment of cancer-related anorexia and cachexia

Authors: Ashlynn Brar[1], Noah Kim[1], Pankaj Soni[1], Kush Shah[2], Jyoti Bajpai[3]

[1] Department of Critical Care, EMC Super Specialty Hospital, Amritsar, Punjab, India

[2] Department of Surgical Oncology, KD Hospital, Gujarat, India

[3] Medical and Precision Oncology, Apollo Hospitals, Chennai, India

Correspondence: Pankaj Soni

Address: Backside Income Tax office, Green Avenue, Amritsar, Punjab 143001, India

Department of Critical Care, EMC Super Specialty Hospital

Tel: +91 7009182189

Email: drsonipankaj@rediffmail.com

Table S1: Network Meta-Analysis of Treatments for Weight Gain

Olanzapin 2.5 mg												
0.78 [-4.1; 5.7]	**Espindolol 20 mg**											
1.34 [-2.6; 5.2]	0.56 [-2.67; 3.79]	**Ponsegromab 400 mg**										
2.22 [-1.6; 6.0]	1.44 [-1.71; 4.60]	0.88 [-0.18; 1.95]	**Anamorelin 100 mg**									
2.23 [-1.7; 6.1]	1.45 [-1.77; 4.67]	0.89 [-0.05; 1.83]	0.01 [-1.03; 1.04]	**Ponsegromab 200 mg**								
2.93 [-0.9; 6.8]	2.15 [-1.06; 5.36]	1.59 [0.67; 2.51]	0.71 [-0.31; 1.72]	0.70 [-0.18; 1.58]	**Ponsegromab 100 mg**							
3.28 [-0.6; 7.2]	2.50 [-0.73; 5.73]	1.94 [0.65; 3.23]	1.06 [0.12; 1.99]	1.05 [-0.21; 2.31]	0.35 [-0.89; 1.60]	**Anamorelin 50 mg**						
3.51 [-1.6; 8.6]	2.73 [0.24; 5.22]	2.17 [-1.42; 5.76]	1.29 [-2.23; 4.80]	1.28 [-2.30; 4.86]	0.58 [-2.99; 4.15]	0.23 [-3.36; 3.81]	**Espindolol 10 mg**					
4.20 [-2.92;11.3]	3.42 [-3.36; 10.2]	2.86 [-3.24; 8.96]	1.98 [-4.08; 8.04]	1.97 [-4.13; 8.07]	1.27 [-4.82; 7.36]	0.92 [-5.19; 7.02]	0.69 [-6.27; 7.65]	**Pentoxifylline 1200 mg**				
4.41 [0.12; 8.70]	3.63 [-0.08; 7.34]	3.07 [0.83; 5.31]	2.19 [0.07; 4.30]	2.18 [-0.04; 4.40]	1.48 [-0.73; 3.69]	1.13 [-1.11; 3.37]	0.90 [-3.13; 4.93]	0.21 [-6.16; 6.58]	**Enobosarm 3 mg**			
4.43 [0.59; 8.26]	3.65 [0.48; 6.82]	3.09 [1.96; 4.22]	2.20 [1.33; 3.07]	2.20 [1.10; 3.29]	1.50 [0.42; 2.58]	1.14 [0.01; 2.28]	0.92 [-2.61; 4.45]	0.23 [-5.84; 6.30]	0.02 [-2.13; 2.17]	**Mirtazapine 15 mg**		
4.68 [0.34; 9.02]	3.90 [0.14; 7.66]	3.34 [1.02; 5.66]	2.46 [0.25; 4.66]	2.45 [0.15; 4.75]	1.75 [-0.55; 4.05]	1.40 [-0.92; 3.72]	1.17 [-2.90; 5.24]	0.48 [-5.92; 6.88]	0.27 [-1.84; 2.38]	0.25 [-1.99; 2.49]	**Enobosarm 1 mg**	
4.60 [0.82; 8.38]	3.82 [0.72; 6.92]	3.26 [2.35; 4.17]	2.38 [1.82; 2.94]	2.37 [1.50; 3.24]	1.67 [0.82; 2.52]	1.32 [0.41; 2.23]	1.09 [-2.38; 4.56]	0.40 [-5.63; 6.43]	0.19 [-1.85; 2.23]	0.17 [-0.50; 0.84]	-0.08 [-2.22;2.06]	**Placebo**

Table S2: Network Meta-Analysis of Treatments for Serious Adverse Events

Enobosarm 1 mg											
0.73 [0.22; 2.40]	**Enobosarm 3 mg**										
0.69 [0.14; 3.46]	0.94 [0.19; 4.59]	**Ponsegromab 200 mg**									
0.89 [0.05; 14.4]	1.21 [0.08; 19.3]	1.29 [0.08; 20.7]	**Olanzapin 2.5 mg**								
0.54 [0.14; 2.04]	0.73 [0.20; 2.69]	0.78 [0.21; 2.91]	0.61 [0.04; 8.38]	**Anamorelin 100 mg**							
0.47 [0.11; 2.11]	0.65 [0.15; 2.80]	0.69 [0.16; 3.01]	0.54 [0.04; 8.04]	0.88 [0.34; 2.30]	**Anamorelin 50 mg**						
0.40 [0.13; 1.28]	0.55 [0.18; 1.68]	0.59 [0.19; 1.82]	0.46 [0.04; 5.77]	0.75 [0.38; 1.47]	0.85 [0.33; 2.20]	**Placebo**					
0.35 [0.07; 1.81]	0.48 [0.10; 2.41]	0.51 [0.16; 1.59]	0.40 [0.02; 6.49]	0.66 [0.17; 2.50]	0.74 [0.17; 3.32]	0.87 [0.27; 2.79]	**Ponsegromab 100 mg**				
0.29 [0.05; 1.68]	0.40 [0.07; 2.23]	0.43 [0.08; 2.40]	0.33 [0.02; 5.77]	0.55 [0.13; 2.37]	0.62 [0.12; 3.11]	0.73 [0.20; 2.68]	0.84 [0.15; 4.79]	**Espindolol 20 mg**			
0.16 [0.02; 1.07]	0.21 [0.03; 1.43]	0.23 [0.03; 1.54]	0.18 [0.01; 3.45]	0.29 [0.05; 1.56]	0.33 [0.05; 2.02]	0.39 [0.08; 1.81]	0.45 [0.06; 3.07]	0.53 [0.12; 2.28]	**Espindolol 10 mg**		
0.12 [0.02; 0.69]	0.17 [0.03; 0.92]	0.18 [0.05; 0.63]	0.14 [0.01; 2.37]	0.23 [0.05; 0.97]	0.26 [0.05; 1.27]	0.30 [0.08; 1.10]	0.35 [0.09; 1.26]	0.41 [0.07; 2.59]	0.78 [0.10; 5.78]	**Ponsegromab 400 mg**	
0.07 [0.02; 0.30]	0.09 [0.02; 0.40]	0.10 [0.02; 0.43]	0.08 [0.01; 1.15]	0.13 [0.04; 0.40]	0.14 [0.04; 0.54]	0.17 [0.07; 0.43]	0.19 [0.04; 0.85]	0.23 [0.05; 1.14]	0.43 [0.07; 2.61]	0.56 [0.11; 2.73]	**Mirtazapine 15 mg**

Figure S1: PRISMA Flowchart of Study Selection




Figure S2: Network Graph of Studies Evaluating Weight Gain




Figure S3: Ranking of Treatments Based on Probability of Weight Gain




Figure S4: Network Graph of Studies Evaluating Improvement in Anorexia-Cachexia Scale




Figure S5: Ranking of Treatments Based on Anorexia-Cachexia Scale Improvement




Figure S6: Network Graph of Studies Evaluating Serious Adverse Events




Figure S7: Ranking of Treatments Based on Serious Adverse Events




Figure S8: Sensitivity Analysis of Serious Adverse Events in Direct Comparison




Figure S9: Sensitivity Analysis of Safety Ranking in Serious Adverse Events




Figure S10: Summary of Risk of Bias

